Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefdinir + clavulanic acid
- Development stage
- Phase 4
- Lead developer
- Neutec
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cefdinir + clavulanic acid is an oral combination antibiotic product composed of cefdinir, a third-generation cephalosporin, and clavulanic acid, a beta-lactamase inhibitor. Cefdinir inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell death. Clavulanic acid irreversibly inhibits a range of beta-lactamase enzymes, which protects cefdinir from degradation by resistant bacteria and extends its antibacterial spectrum. This combination is primarily indicated for the treatment of respiratory tract infections due to susceptible bacteria.
- Brand names
- FULLCEF PLUS
- Other names
- Clavulanic Acid/Cefdinir film coated tablets
02
Targets
β-lactamasePBP2 (Penicillin-binding protein 2)
Beyond the preview
Go deeper on cefdinir + clavulanic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefdinir + clavulanic acid.